The devil's in the details by Petsko, Gregory A
Th   e Health Care Reform Bill that was recently passed by 
the US Congress and signed into law by President Obama 
has admirably simple goals: to provide health care 
beneﬁ  ts to some 30+ million Americans who currently 
have none, and to begin to control the spiraling cost of 
health care, which is threatening to make a shambles of 
the US economy. But, as my mother was fond of saying, 
the devil’s in the details, and at 2,562 pages of almost 
unreadable prose, there are a lot of details for the devil to 
hide in. Th  is shouldn’t detract from the extraordinary 
achievement of President Obama and the Democratic 
Party leadership in Congress; by simply getting the bill 
passed, they accomplished something that presidents 
since Th   eodore Roosevelt have failed to do.
Still, there is one particular detail that is worth 
scientists in general - and maybe genome biologists in 
particular - paying some attention to. It goes by the rather 
unglamorous name of SA 2688, and it’s an amendment to 
the bill. It was inserted into the ﬁ  nal package by Penn-
sylvania Senator Arlen Specter, a longtime champion of 
biomedical research and increased funding for the US 
National Institutes of Health (NIH). Th  e amendment is 
8 pages long, so I can’t quote it in detail, but here’s a 
summary of what it says.
Th  e amendment creates a program called the Cures 
Acceleration Network (CAN) within the Oﬃ   ce  of  the 
NIH Director (with a 24-member oversight board). CAN 
is to “award grants and contracts to eligible entities… to 
accelerate the development of high need cures, including 
through the development of medical products and 
behavioral therapies”. A high need cure is deﬁ  ned as a 
product that “is a priority to diagnose, mitigate, prevent, 
or treat harm from any disease or condition; and for 
which the incentives of the commercial market are 
unlikely to result in its adequate or timely development”. 
CAN’s functions include: conducting and supporting 
revolutionary advances in basic research; translating 
scientiﬁ  c discoveries from bench to bedside; awarding 
grants and contracts to eligible entities; providing the 
resources necessary for government agencies, private 
companies, academic institutions, and investigators to 
develop high need cures; reducing the barriers between 
laboratory discoveries and clinical trials for new thera-
pies; and facilitating review in the Food and Drug Adminis-
tration (FDA) for the high need cures funded by CAN.
Th  e board consists of 24 members, serving 4 year 
terms. At least one individual eminent in each of the 
following ﬁ   elds will be appointed: basic research; 
medicine; biopharmaceuticals; discovery and delivery of 
medical products; bioinformatics and gene therapy; medical 
instrumentation; and regulatory review and approval of 
medical products. In an unprecedented move, an addi-
tional four individuals from private venture capital ﬁ  rms 
will also be appointed, as well as eight represen  tatives of 
disease advocacy organizations.
Finally, ex oﬃ   ci  o members will include a representative 
from each of the NIH, the Department of Defense Health 
Aﬀ  airs oﬃ   ce, the US National Science Foundation, and 
the FDA, the regulatory body that oversees the safety and 
eﬀ  ectiveness of medicines and treatments. Th   e Board is 
to advise the NIH Director on ‘signiﬁ  cant barriers’ to 
successful translation of basic science into clinical appli-
ca tion.  Th  e Board will provide recommendations to the 
Director if such a barrier is identiﬁ  ed. If the NIH Director 
does not accept such a recommendation, he must explain 
to the Board why he has not done so.
Th   e CAN sets up a series of grant programs designed 
to facilitate the development of high need cures that are 
in compliance with FDA standards on the drug develop-
ment and approval process. Eligible entities include 
private or public research institutions, academic institu-
tions, medical centers, biotechnology or pharmaceutical 
companies, disease or patient advocacy organizations, or 
academic research institutions.
Th  ere are three types of awards: ﬁ   rst, the Cures 
Acceleration Partnership Awards, which provide up to 
$15 million per project for the ﬁ  rst year, in one lump 
sum. It seems that additional increments of up to 
$15 million can be applied for in subsequent ﬁ  scal years 
(but it is not clear whether more than one additional year 
of funding is allowed). Th   e recipient must also come up 
with non-Federal matching funds in a ratio of $1 for each 
$3 of Federal funds received. Th   e matching-fund require-
ment can be waived by the director. Second, there are the  © 2010 BioMed Central Ltd
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at up to $15 million the ﬁ  rst year, with at least one follow-
up funding cycle of up to an additional $15 million 
possible. Th   ere is no matching requirement for this type 
of award. Finally, there are the Cures Acceleration 
Flexible Research Awards, which allow the NIH director 
to use ‘other transactions’ besides contracts, grants, or 
cooperative agreements to carry out the goals and 
objectives of the award program. No more than 20% of 
the total funds available for the CAN program can be 
spent in this manner. Th  e CAN is authorized at $500 
million in 2010, with additional funds as required for 
each of the next 10 years.
On the surface, this sounds like a great idea, and one 
that might help improve the image of federally-funded 
scientiﬁ  c research with the general public. But the devil is 
in the details, and to understand that, I need to take a 
moment to explain a peculiarity of American civics to my 
non-US readers.
Th   ere are two major kinds of legislation that Congress 
can pass when it wants to establish new programs: 
authorizations and appropriations. Authorizing legisla-
tion is that “which authorizes the appropriation of funds 
to implement” laws that create agencies, programs or 
government functions. It does not give a government 
agency permission to write a check or enter into a 
contract. Rather, its purpose is to set parameters for 
government agencies and programs. An appropriations 
act, on the other hand, confers budget authority on 
federal agencies to incur obligations. In other words, 
authorizing legislation sets policies and funding limits for 
agencies/programs, whereas appropriations legislation is 
what a department or agency needs to obtain new money 
from the government to actually fund that agency or 
program. In the absence of an appropriation, agencies 
must ﬁ  nd the money they need to satisfy an authorization 
by taking it away from other funded activities: this is the 
dreaded ‘unfunded mandate’ that drives administrators 
to distraction.
SA 2688 is - you guessed it - an authorization without 
an appropriation. It requires the NIH to spend $500 
million a year for 10 years (about 1.7% of its current 
$30  billion budget), but it does not provide any new 
money to pay for it. So the money must come from 
somewhere, and the big fear among many in the scientiﬁ  c 
community is that it will come from the pool of individual 
investigator-initiated research support, which has no 
single large political constituency to ﬁ  ght for it, rather 
than, say, some of the large, disease-focused programs 
that are closely watched over by the patient advocacy 
organizations. Th  is is a particular problem right now, 
because the NIH is facing a potential ‘budget cliﬀ  ’ in 
ﬁ  scal year 2011, when the stimulus funds that Congress 
appropriated in response to the ﬁ  nancial crisis expire, 
and the base NIH budget becomes ﬂ  at again. Bleeding 
$500 million - or even a fraction of it - from the individual 
research grant pool would turn that cliﬀ   into an abyss.
Th  ere are various alternatives for ‘ﬁ  nding’ the money 
that the community should urge the NIH Director to 
look into. One would be to allow each of the disease-
oriented Institutes and Centers of the NIH to designate 
grants and programs they are already funding as CAN 
programs - provided, of course, that they meet the 
general parameters of the authorization. Th  at would 
allow CAN to coexist peacefully with the existing 
research that NIH supports.
But, whereas I like that idea, I’d like to see another one 
debated ﬁ  rst, because there’s a chance that I’d like it even 
more. It involves transforming the RoadMap program, 
which is already administered out of the NIH Director’s 
oﬃ   ce, into CAN.
Th   e RoadMap was the brainchild of Elias Zerhouni, the 
former NIH Director (the agency is now headed by 
Francis Collins, a genome biologist). Th   e purpose was to 
identify major opportunities and gaps in biomedical 
research that no single institute at NIH could tackle alone 
but that the agency as a whole needed to address, to 
make the biggest impact on the progress of medical 
research. Doesn’t that sound exactly like what CAN is 
also concerned about? Th   e RoadMap has never received 
the unqualiﬁ   ed support of the biological science 
community, chieﬂ  y because they saw it as taking money 
and attention away from important fundamental research 
and channeling it into lower-quality, clinically oriented 
studies that often didn’t go anywhere.
Th   e CAN authorization provides a golden opportunity 
to reinvent this program in a way that Congress and the 
disease advocates would both love, while doing some 
very useful work. What’s wrong with that? Well, nothing, 
but the devil’s in the details. Read the wrong way, CAN 
could turn ﬁ   rst-rate biomedical research programs at 
NIH and elsewhere into third-rate pharmaceutical 
endeavors. Th  at would be a disaster, because the Bill 
greatly underestimates the cost of bringing a therapy to 
the clinic (almost $1 billion for a small-molecule drug, a 
third to a half of that for a biopharmaceutical), and risks 
promising the public cures that will take over a decade to 
materialize. Such an approach would also set the 
advocates for diﬀ   erent diseases in direct competition 
with one another for this pot of money, which is the 
major reason I oppose focusing CAN on any one disease 
or set of diseases.
Why not, instead, take CAN at its word? It wants to 
accelerate the ﬁ  nding of cures, so let’s focus it on the 
major bottlenecks to going from fundamental scientiﬁ  c 
discoveries to actual cures, for all diseases.
Th   ere are many of these. I think CAN should pick, say, 
two or three of them and make those its focus for the 
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grants should be asked to address, and the money should 
be the money that is currently being spent on the 
RoadMap. Here are my personal favorites, but there are a 
few more that could also be imagined:
A major bottleneck is the inability to make analogs of 
complex organic molecules rapidly, especially those 
containing more than one asymmetric center. NIH still 
funds some research on the development of new 
synthetic methods in organic chemistry, but it used to 
fund a lot more. Th   is is an opportunity for it to get back 
into that very important business.
Natural products are still very important sources of 
drugs, but they are hard to separate from the complex 
mixtures found in the wild and even harder to charac-
terize and synthesize. CAN could throw some serious 
resources at the development of better methods to do 
these things.
Our animal models for toxicity are pretty good, but our 
animal and cell culture models for many diseases are 
terrible (this is particularly true for the major 
neurological disorders). Comparative assessments of all 
existing disease models, followed a program to fund the 
development of better ones where needed, would have a 
major impact on the pace of drug discovery, because such 
improved models would allow therapeutics to fail much 
earlier in the drug development pipeline, before expen-
sive clinical trials are initiated.
Th   e blood-brain barrier is one major reason that many 
pharmaceutical companies are abandoning their pro-
grams in central nervous system (CNS) diseases. It is very 
diﬃ   cult to predict the CNS availability of a compound in 
humans without doing actual trials. Th  e blood-brain 
barrier is a combination of restricted permeability of the 
brain to compounds in the blood with speciﬁ  c  eﬄ   ux 
pumps that export many drug-like substances. We need 
ways to design CNS-available compounds from ﬁ  rst 
principles if we really wish to accelerate the development 
of cures for disorders such as Alzheimer’s disease.
Most biopharmaceuticals are immunogenic, even when 
they are human proteins, and some of them are seriously 
so. One of the main reasons is that misfolded or 
aggregated proteins break tolerance, and the manu-
facture, storage and delivery of therapeutic biological 
macromolecules contains numerous opportunities for 
proteins to denature. Development of improved methods 
to form and maintain the native structure of these 
molecules would remove a signiﬁ  cant obstacle to their 
increased use.
Th   ere’s one more I would strongly suggest, but I don’t 
have room to discuss it here. I’ve written about it in a 
commentary in our sister publication, BMC Biology, the 
ﬂ  agship journal of the BMC series. Th   e main point I am 
trying to make is that we should use CAN as an 
opportunity to energize the biomedical research commu-
nity to tackle some of the major roadblocks to the 
develop  ment of therapeutics in general. Th   at is, we need 
to make major improvement to the details of how we do 
such development, after all, when it comes to such 
development, the devil is in the details, and if we’re going 
to beat the devil, those details are where we need to focus 
more eﬀ  ort.
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